Humanized and chimeric anti-properdin antibodies

Details for Australian Patent Application No. 2011224224 (hide)

Owner NovelMed Therapeutics, Inc.

Inventors Bansal, Rekha

Agent Fisher Adams Kelly

Pub. Number AU-A-2011224224

PCT Pub. Number WO2011/112850

Priority PCT/ US2011/026841 02.03.11 US; 61/312,469 10.03.10 US; 12/920,997 03.09.10 US

Filing date 10 March 2011

Wipo publication date 15 September 2011

International Classifications

C07K 16/18 Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/46 Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

Event Publications

1 November 2012 PCT application entered the National Phase

  PCT publication WO2011/112850 Priority application(s): WO2011/112850

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011224238-Parenteral formulations of macrolide antibiotics

2011224221-Apparatus for vapor phase processing ophthalmic devices